Chronic Rhinosinusitis With Nasal Polyps CRSWNP

CRSwNP EVEREST

Management of ALLERGIC FUNGAL RHINOSINUSITIS (AFRS): A sever type 2 Inflammatory Disease

The management of AFRS remains challenging to reduce disease burden and limit potential structural damage complications

Loss of Smell Is a Key Symptom in CRSwNP

Loss of Smell Improvement in Patients With CRSwNP

EPOS2020/EUFOREA Expert Opinion on Defining Disease States and Therapeutic Goals in CRSwNP

An expert panel convened by EPOS2020 and EUFOREA proposed standardized definitions for disease control, remission, and progression in CRSwNP. This initiative aims to harmonize and optimize the standard of care for patients with CRSwNP.

IL-4 and IL-13 are key and central cytokines with unique and overlapping roles contributing to the pathophysiology of CRSwNP

You can imagine more than 90% of CRSwNP patients losses their ability's of smell

“Smell—we call it the Cinderella of the senses"

What can biologic treatment do for patients with CRS with nasal polyps?

What does patient empowerment mean for your treatment plan?

Hear from an expert on what have you learned from your experience with biologics?

How does Dupixent help recover smell?

Hear from an expert on would you consider a biologic for a Surgery-naïve Patient with CRS with Nasal Polyps?

Type 2 Inflammation is the underlying cause of CRSwNP in 80% of Patients.

Hear From An Expert On The Type 2 Immune Response And Inflammation

Hear from an expert on how do you address Patients' concerns about Sinus surgery?

Hear from an expert on Identifying Patients who are appropriate candidates for Biologic treatment

Look beyond the symptoms to identify and manage Patients with Type 2 Inflammation

Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?

Hear from an expert on how can you limit the effects of systemic steroid use for Patients with CRS with Nasal Polyps?

Expert opinions: Would you consider a biologic for a CRSwnp patient who has had Sinus surgery?

Daily Burden of CRSwNP